secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0001437749-23-003646
Event type: leadership
Sentiment:  negative
Materiality: 0.80
Item codes: 1.02, 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Diffusion cuts nearly half of staff, pauses lead drug study; CMO departs
------------------------------------------------------------------------

- Reduction in force affecting 6 of 13 employees (~46% cut) as cash preservation measure.
- Company pauses Phase 2 study of TSC in newly diagnosed GBM; evaluating sale or out-license of TSC.
- Expects $1.1M one-time charge in Q1 2023 for termination benefits.
- Chief Medical Officer Dr. Christopher Galloway departs effective March 1, 2023; separation includes 9 months salary, pro-rated bonus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774923003646/0001437749-23-003646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774923003646/dffn20230216_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-003646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer